Invivoscribe Marketing, Author at Invivoscribe

About Invivoscribe Marketing

This author has not yet filled in any details.
So far Invivoscribe Marketing has created 146 blog entries.

Invivoscribe – EHA 2019: Part 1 of 3

Invivoscribe Marketing2022-05-25T03:01:00-07:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Invivoscribe Marketing2021-02-15T20:01:10-08:00June 6th, 2019|2019 Publications, Publications|

Invivoscribe – ASCO – LeukoStrat CDx FLT3 Mutation Assay

Invivoscribe Marketing2022-05-25T03:01:00-07:00June 1st, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies

Invivoscribe Marketing2021-02-26T19:10:45-08:00May 21st, 2019|2019 Press Releases, Press Releases|

AMP Global 2019 Video Series Part 4 of 4

Invivoscribe Marketing2022-05-25T03:01:01-07:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 3 of 4

Invivoscribe Marketing2022-05-25T03:01:01-07:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 2 of 4

Invivoscribe Marketing2022-05-25T03:01:01-07:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 1 of 4

Invivoscribe Marketing2024-08-12T18:42:43-07:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

Invivoscribe Marketing2021-02-11T23:46:14-08:00March 21st, 2019|2019 Publications, Featured Publications, Publications|

US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US

Invivoscribe also Receives National Reimbursement for CDx Assay in Japan

Invivoscribe Marketing2021-02-26T19:11:02-08:00November 29th, 2018|2018 Press Releases, Press Releases|

Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib

Invivoscribe Marketing2022-09-23T16:52:06-07:00November 27th, 2018|2018 Press Releases, Press Releases|

Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan

Invivoscribe Marketing2021-02-26T19:11:48-08:00November 19th, 2018|2018 Press Releases, Press Releases|

Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)

Invivoscribe Marketing2021-02-26T19:12:02-08:00September 27th, 2018|2018 Press Releases, Press Releases|

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Invivoscribe Marketing2021-02-11T23:49:39-08:00August 25th, 2018|2018 Publications, Featured Publications, Publications|

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Invivoscribe Marketing2021-02-11T23:54:51-08:00August 22nd, 2018|2018 Publications, Featured Publications, Publications|

Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels

Invivoscribe Marketing2021-02-26T19:12:15-08:00May 9th, 2018|2018 Press Releases, Press Releases|

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

Invivoscribe Marketing2021-02-26T19:12:23-08:00May 8th, 2018|2018 Press Releases, Press Releases|

Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive Immunotherapy

Invivoscribe Marketing2021-02-12T21:23:31-08:00November 11th, 2017|2017 Publications, Publications|

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Invivoscribe Marketing2021-02-12T00:14:15-08:00August 9th, 2017|2017 Publications, Publications|

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia

Invivoscribe Marketing2021-02-12T00:59:47-08:00July 3rd, 2017|2017 Publications, Publications|

In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis

Invivoscribe Marketing2021-02-12T01:06:38-08:00June 20th, 2017|2017 Publications, Publications|

Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients

Invivoscribe Marketing2021-02-12T00:57:59-08:00June 17th, 2017|2017 Publications, Publications|

T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing

Invivoscribe Marketing2021-02-12T00:17:56-08:00May 30th, 2017|2017 Publications, Publications|

Molecular pathology diagnosis of diffuse large B cell lymphoma using BIOMED-2 clonal gene rearrangements

Invivoscribe Marketing2021-02-12T01:03:26-08:00April 27th, 2017|2017 Publications, Publications|

A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma

Invivoscribe Marketing2021-02-12T01:10:12-08:00April 17th, 2017|2017 Publications, Publications|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

About Invivoscribe Marketing

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.